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Abstract
Background:  Tumor Necrosis Factor-α  (TNF-α ) has been implicated in the pathogenesis of
insulin resistance and obesity. The increased expression of TNF-α  in adipose tissue has been shown
to induce insulin resistance, and a polymorphism at position -308 in the promoter region ofTNF-α
has been shown to increase transcription of the gene in adipocytes. Aim of this study is to
investigate the role of the G-308A TNFα  variant in obesity and to study the possible influence of this
mutation on body fat distribution and on measures of obesity (including Fat Free Mass, Fat Mass,
basal metabolic rate), insulin resistance (measured as HOMAIR), and lipid abnormalities. The G-
308A TNFα  polymorphism has been studied in 115 patients with obesity (mean BMI 33.9 ± 0.5) and
in 79 normal lean subjects (mean BMI 24.3 ± 0.3).
Methods:  The G-308A variant, detected by PCR amplification and Nco-1 digestion, determines
the loss of a restriction site resulting in a single band of 107 bp [the (A) allele].
Results:  The (A) allele frequencies of the G-308A TNFα  polymorphism were 13.1% in the obese
group and 14.6% in the lean subjects, with no significant difference between the two groups.
Furthermore, no association was found with BMI classes, body fat distribution, HOMAIR, and
metabolic abnormalities.
Conclusions:   Our study did not detect any significant association of the G-308A TNFα
polymorphism with obesity or with its clinical and metabolic abnormalities in this population. Our
data suggests that, in our population, the G-308A TNFα  polymorphism is unlikely to play a major
role in the pathogenesis of these conditions.
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Background
Insulin resistance leading to defects in glucose and/or li-
pid metabolism is a characteristic feature of both obesity
and type 2 diabetes. In obesity increased visceral fat dis-
tribution is considered important for the development of
insulin resistance. Many evidences have linked Tumor
Necrosis Factor-alpha (TNF-α ) to the metabolic abnor-
malities of insulin resistance. Adipose tissue has been
shown to be a site for TNF-α  synthesis, with a direct cor-
relation between levels of TNF-α , obesity and hyperin-
sulinemia [1]. It has been suggested that TNF may act as
an important auto/paracrine regulator of fat cell func-
tion which serves to limit adipose tissue expansion,
probably by inducing insulin resistance which may in
turn cause metabolic disturbances
In vitro studies on cultured cells suggested that TNF-α
may exert its anti-insulin effect by suppressing the phos-
phorylation of the insulin receptor and its substrates [2].
In transgenic animals overexpression of TNF-α  mRNA
in adipose tissue is associated with insulin resistance [3].
Neutralisation of circulating TNF-α  in insulin-resistant
obese mouse leads to a significant increase in insulin
sensitivity, suggesting that elevated TNF-α  levels may
contribute to development of insulin resistance [4]. It
has also been demonstrated that TNF-α  blocks the action
of insulin through its ability to inhibit insulin receptor ty-
rosine kinase activity [4–7] although other mechanisms,
such as quantitative regulation of glucose transporters,
have also been proposed [8].
Linkage analysis has shown that a marker near the TNF-
α  region on chromosome 6p21 was significantly linked
with obesity in Pima Indians [9]. Mutation analysis has
identified a G →  A transition in the promoter region of
TNF-α  at position -308. This polymorphic variant has
been shown to affect the promoter region of the TNF-α
gene leading to a higher rate of transcription compared
to the common allele [10]. Several association studies
have been conducted on the G-308A variant, with con-
flicting results. Fernandez-Real and co-workers [11] have
reported a significant association between the G-308A
variant and insulin sensitivity, increased BMI and in-
creased production of leptin, suggesting an important
role in overeating and obesity. Furthermore, when the
presence of the G-308A variant was correlated to meas-
ures of body fat analysed by bioelectric impedance, a sig-
nificant association with percent body fat was found in
obese subjects [11]. A recent Swedish study has found a
correlation between increasing BMI and this mutation
but only in females [12]. However, many other studies
have reported negative results, with no correlation be-
tween this TNF-α  mutation and insulin resistance or any
other metabolic abnormality of the insulin resistance
syndrome [13–15]. Moreover, large cohort studies in
Chinese, Caucasians and American blacks did not shows
significant correlation between G-308A polymorphism
and insulin resistance or obesity [16,17], suggesting, if
present, only a marginal role of TNF-α  in the pathogene-
sis of these metabolic conditions.
Aim of this study is to investigate in an Italian population
the role of the G-308A TNF-α  variant in obesity and to
study its relation to body fat distribution, insulin resist-
ance measured by HOMAIR, and metabolic abnormali-
ties.
Methods
A total number of 194 Caucasian subjects were studied.
The 115 obese subjects were consecutively recruited from
the obesity clinic of the department of Clinical Sciences,
University of Rome "La Sapienza". All obese patients
were recruited on the basis of BMI > 28 Kg/m2, accord-
ing to previously suggested criteria [18]. Body fat distri-
bution was assessed by waist circumference (WC); the
cut-points chosen to differentiate central from peripher-
al obesity were the following: WC>94 for men and
WC>88 for women. These limits involve a trade-off be-
tween sensitivity and specificity and were recently de-
scribed by Kopelman [19]. Furthermore, these limits
take into account the metabolic complications of the an-
droid biotype. Ninety-eight of the obese subjects under-
went bioelectric impedance for the determination of fat-
free mass (FFM), fat mass (FAT), basal metabolic rate
and % total body water (TBW) (Datasystem vers. 1, Med-
igroup Milan, Italy). Total fat mass was determined by
subtracting FFM from total body weight. The accuracy of
FFM determination was increased by using a multifre-
quency bioimpedance (1–5–10–50–100 KHz) and ap-
plying the equation described by Segal et al. [20].
Exclusion criteria were: presence of type 2 diabetes or
first degree relatives with type 2 diabetes, presence of
thyroid, liver or renal disease and presence of coronary
artery disease (CAD).
Control subjects (n = 79) were unrelated individuals ran-
domly chosen from a population of free living individuals
screened for CAD risk factors. Exclusion criteria were:
presence of BMI > 26, presence of type 2 diabetes or
presence of type 2 diabetes in a first degree relative and
presence of CAD. CAD was excluded by using the Rose
questionnaire and ECG (Minnesota coding) [21]. In both
obese and control subjects a complete medical history
was obtained with a questionnaire and laboratory pa-
rameters including total cholesterol, HDL, LDL, triglyc-
erides, blood glucose and fasting plasma insulin were
evaluated as well.
The transition polymorphism G to A in the -308 position
of the TNF-α  gene was detected by PCR amplification asBMC Medical Genetics 2001, 2:10 http://www.biomedcentral.com/1471-2350/2/10
previously described [11], with the following primers: 5'-
AGGCAATAGTTTTGAGGGCCAT-3' and 5'-TCCTCCCT-
GCTCCGATTCCG-3'. PCR products were digested with
10-fold excess Nco I restriction enzyme at 37°C for 45
minutes and visualised on 3% high resolution agarose gel
stained with ethidium bromide. Nco I restriction diges-
tion reveals a two-allele polymorphism that produces 3
bands of different sizes: a 107 bp fragment correspond-
ing to the A allele (restriction site absent) and a set of 87
and 20 bp corresponding to the G allele (restriction site
present, the wild-type).
Plasma insulin levels were measured on frozen sample
using a radioimmunoassay (Biodata Insulin Kit, Milan,
Italy) with an interassay coefficient of variation of 7.5 %.
Homeostasis model assessment for insulin resistance
(HOMAIR) was calculated as described by Matthews et al
[22].
Categorical variables were compared by chi-square or
Fisher's exact test. Differences between continuous vari-
ables were evaluated by two-tailed Student's test. All p-
values were corrected for differences in age. Genotype
distributions between the study groups were compared
by 2X2 and 2X3 contingency table and chi-square analy-
sis.
Results
The clinical characteristics of the study subjects are
shown in table 1. Obese and lean subjects were signifi-
cantly different in age (p < 0.01); the two groups were
comparable for sex distribution. Obese subjects showed
higher fasting plasma insulin (p < 0.0001), although in
the normal range, but there was no statistical difference
in blood glucose between the two groups. The homeosta-
sis model of assessment for insulin resistance (HOMAIR)
was significantly higher in the obese group (p < 0.0003),
indicating the presence of lower insulin sensitivity in the
obese subjects, as expected. There was no difference be-
tween the two groups in the lipid profile.
Ninety-eight obese subjects were studied by bioelectric
impedance and were divided into subjects with central
and peripheral obesity, according to their body fat distri-
bution: Body fat distribution was assessed by waist cir-
cumference (WC), which provides measures of upper
body fat deposition and correlates with an increased risk
of metabolic and cardiovascular complications [19]. In
comparison with subjects with peripheral obesity, those
with central obesity were significantly older (51.2 ± 1.6
vs. 39.4 ± 2.5, p < 0.001), had a higher BMI (35.5 ± 0.7
vs. 32.7 ± 1.9, p < 0.01) and a wider waist circumference
(108.9 ± 5.0 vs. 90.6 ± 2.4, p < 0.0007). Centrally obese
subjects were significantly different in fat-free mass and
fat mass (0.007, data not shown). Furthermore, al-
though fasting blood glucose and insulin were not signif-
icantly different between groups, HOMAIR was
significantly higher in subjects with central obesity (5.79
± 0.6 vs. 4.04 ± 0.4; p < 0.04), strongly suggesting the
presence of a lower level of insulin sensitivity in this sub-
group. Finally, total cholesterol, triglycerides and LDL
cholesterol were significantly higher in patients with
central obesity compared to the peripheral obesity sub-
group (p < 0.01), although no difference was found in
HDL cholesterol. Overall, these data confirm the expect-
ed findings of a worse metabolic profile in subjects with
central obesity compared to those with peripheral obesi-
ty.
Table 1: Clinical characteristics of study subjects
Obese subjects Lean subjects p-value
(n = 115) (n = 79)
Age (yrs) 47.04 ± 1.3 51.36 ± 1.8 P < 0.01
Sex (M/F) 37 / 78 27/52 NS
BMI (kg/m2) 33.93 ± 0.512 24.30 ± 0.313 <0.0001
Blood glucose (mg/dl) 91.56 ± 2.0 86.84 ± 10.08 NS
Fasting plasma insulin (µU/ml) 22.72 ± 1.7 9.29 ± 1.04 <0.0001
HOMAIR 5 ± 0.16 2.2 ± 0.45 <0.0003
Plasma lipids (mg/dL)
Total cholesterol 218.69 ± 4.5 214.95 ± 6.1 NS
HDL cholesterol. 48.16 ± 1.4 48.2 ± 2.2 NS
Total triglycerides 156.85 ± 12.5 157.26 ± 12.96 NS
LDL cholesterol 128.61 ± 5.1 131.2 ± 5N S
Data are given as means ± SEM. All p-values were corrected for differences in age The statistical analysis of total triglycerides and plasma insulin were 
performed on log-trasformed values, but the untrasformed values are given in table. Continuous variables were compared by t-test and categorical 
variables by Χ 2 test.BMC Medical Genetics 2001, 2:10 http://www.biomedcentral.com/1471-2350/2/10
The distribution of the G-308A genotypes and allele fre-
quencies between obese and control subjects was not sta-
tistically different (table 2). Observed frequencies were
in Hardy-Weinberg equilibrium. Allele frequencies in
the control group were similar to that reported in other
studies [14,17] in different ethnic groups. Furthermore,
no significant difference was found when the two sub-
groups of obese subjects (centrally and peripherally
obese) were analysed, indicating that the TNF-α  poly-
morphism is not associated with body fat distribution
(table 2). Finally, we did not find any association with
gender (data not shown).
Assuming a dominant model of inheritance (only 4 sub-
jects were homozygous for the mutation), we compared
metabolic parameters between GA and AA carriers (n =
145) vs. non-carriers (GG) (n = 49) (table 3). There was
no significant difference in fasting blood glucose, fasting
plasma insulin nor in HOMAIR, suggesting a non-inter-
ference between glucose metabolic pathways and TNF-α
gene. No significant difference was also detected be-
tween the groups in both lipid profile and body fat distri-
bution parameters (TBW, FFM; FAT). There was a
significant association between a lower BMI (p < 0.05)
and carrier status. However, when the p-value was cor-
rected for multiple comparisons this analysis did not
reach significance.
Finally, in order to further investigate if there was a dif-
ference in frequency of the G-308A variant between dif-
ferent grades of BMI, we divided all the 194 subjects into
three BMI classes according to WHO criteria [18] (table
4). In class 1 there were subjects with BMI < 25, in class
2 subjects with BMI = 25–29.9, in class 3 subjects with
BMI > 30. Even if there was a slight decrease in hetero-
zygosity with BMI increase, there was no significant dif-
ference in the frequency of the TNF-α  variant between
classes.
Discussion
Many evidences link TNF-α  to the metabolic abnormali-
ties of insulin resistance. Studies in cells suggested that
TNF-α  has an anti-insulin effect by suppressing the
phosphorylation of the insulin receptor and its sub-
strates [2,4–7]. Neutralisation of circulating TNF-α  by in
vivo injection of soluble TNF-α  receptor-immunoglobu-
lin G chimeric protein leads to a significant increase in
insulin sensitivity [23], and infusion of TNF-α  during
euglycemic hyperinsulinemic clamp blocks approxi-
mately half of the glucose uptake by muscle [24], sug-
gesting that elevated TNFα  levels may contribute to
development of insulin resistance. The G-308A mutation
in the promoter region of TNF-α  acts in vitro as a much
stronger trascriptional activator than the wild-type TNF-
α [10], and it was suggested that a higher transcriptional
activity would result in raised TNF-α  concentrations fol-
lowed by decreased insulin sensitivity [10]. However, the
concentrations of circulating TNF-α  measured in vivo in
individuals with different degrees of obesity and insulin
resistance did not correlate with metabolic abnormali-
ties [25].
A wealth of genetic studies on the possible role of TNF-α
in the etiopathogenesis of insulin-resistance and/or its
associated metabolic abnormalities have yielded con-
flicting results. Linkage has been detected between a
marker near TNF-α  and obesity in Pima Indians [9] and
a further study in a small population (38 subjects) [11]
has confirmed this result showing a rise in BMI and fast-
ing plasma insulin in subjects carrying the G-308A TNF-
α  polymorphism. Results from more recent studies
[14,15] investigating TNF-α  gene effects on lipid and glu-
cose metabolism were at variance with previous studies:
Table 2: Genotype distributions and allele frequencies for G-308A mutation in theTNF-α  gene in obese subjects and controls
Genotypes Allele frequencies
n. GG GA AA G A
Total obese subjects* 115 87 (75.6%) 26 (22.6%) 2 (1.8%) 0.869 0.131
– Central obesity # 61 50 (81.9%) 11 (18,1%) - 0.909 0.091
– Peripheral obesity § 37 28 (75.6%) 9 (24.4) - 0.878 0.122
Lean subjects 79 58 (73.4%) 19 (24.%) 2 (2.%) 0.854 0.146
GG, GA, and AA = TNF-α  genotypes. Total obese subjects includes 17 patients whom did not undergo biolectric impedance analysis * Total obese 
subjects vs controls: genotypes Χ 2 = 0.21, df = 2, p < NS; allele frequencies Χ 2 = 0.09, df = 1, p < NS. # Central obese subjects vs controls: genotypes 
Χ 2 = 2.4, df = 2, p < NS; allele frequencies Χ 2 = 1.4, df = 1, p < NS. § Peripheral obese subjects vs controls: genotypes Χ 2 = 0.95, df = 2, p < NS; 
allele frequencies Χ 2 = 0.16, df = 1, p < NS. Central obese subjects vs peripheral obese subjects: genotypes Χ 2 = 0.5, df = 1, p = NS; allele frequencies 
Χ 2 = 0.4, df = 1, p = NS. Cutpoints for centrally obese subjects were : WC 94 for men and WC 88 for womenBMC Medical Genetics 2001, 2:10 http://www.biomedcentral.com/1471-2350/2/10
thus, no correlation with either metabolic (fasting insu-
lin, fasting glucose, HOMAIR) or anthropometric param-
eters (body fat distribution, FFM, TBW) were found,
suggesting that there is no association between TNF-α
polymorphism and these parameters.
Due to these contrasting results, the question of whether
TNF-α  gene is involved or not in the pathogenesis of an
altered state in glucose metabolism and obesity still re-
mains to be answered. Our results show no association
between the TNFα  G-308A mutation and fasting plasma
insulin or HOMAIR, suggesting no link between TNFα  G-
308A mutation and decreased insulin sensitivity in our
population
Moreover, comparison of anthropometric parameters
between centrally and peripherally obese subjects did
not show significant differences according to their TNFα
polymorphism status, suggesting that the TNFα  G-308A
mutation does not play an important role in body fat dis-
tribution and its related parameters. Finally, no associa-
tion between the G-308A polymorphism of TNFα  gene
and BMI was found in our cohort, a result similar to that
found in previous studies [14–16]. Only a recent Swedish
study [12] has detected a correlation between increasing
BMI and this mutation, but only in females. In our study
we did not find any association with gender.
In conclusion, our results suggest that the G-308A muta-
tion of the TNFα  gene is unlikely to play an important
role in the development of obesity and its related meta-
bolic abnormalities, such as insulin resistance and dysli-
pidemia, in this Italian population. These results are also
in agreement with many other studies in different popu-
lations. It is possible that alterations in TNFα  are the
consequence, and not the primary cause, of the metabol-
ic abnormalities found in insulin-resistance and its asso-
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Table 3: Comparison of BMI and of metabolic parameters according to theTNF-α  genotypes
Total subjects
GG GA + AA p-value
(n. = 145) (n = 49)
Age (yrs) 48.9 ± 1.3 49.4 ± 1.8 NS
Body Mass Index (kg/m2) 31.6 ± 0.6 29.1 ± 0.7 <0.05*
Blood glucose (mmol/L) 5.06 ± 01 4.79 ± 0.2 NS
Fasting plasma insulin (µU/ml) 18.9 ± 1.5 21.4 ± 3.8 NS
HOMA IIR 4.34 ± 0.3 4.79 ± 0.2 NS
Plasma lipids (mmol/L)
Total cholesterol 219.0 ± 4.4 214.4 ± 6.8 NS
Total triglycerides 154.2 ± 11.4 156.1 ± 15.6 NS
HDL cholesterol 48.5 ± 1.4 47.2 ± 2.8 NS
LDL cholesterol 132.5 ± 4.1 127.3 ± 7.1 NS
Data are given as means ± SEM. All p-values were corrected for differences in age GG, GA, and AA = TNF-α  genotypes. * p-value after correction = 
not significant. The statistical analysis of total triglycerides and plasma insulin were performed on log-trasformed values, but the untrasformed values 
are given in table. Continuous variables were compared by t-test and categorical variables by Χ 2 test.
Table 4: TNF-α  genotype frequencies among subjects with in-
creasing BMI
TNFα  G-308A
Degree of obesity n. GG GA AA
Class 1 38 27 (71.0%) 10 (26.3%) 1 (2.7%)
Class 2 60 43 (71,7%) 14 (23.6%) 3 (4.7%)
Class 3 96 76 (79.1%) 20 (20.9%) -
As previously described (17), the total 194 subjects in this study were 
divided in 3 BMI classes: in class 1 subjects with BMI < 25, in class 2 sub-
jects with BMI = 25–29.9, in class 3 subjects with BMI > 30BMC Medical Genetics 2001, 2:10 http://www.biomedcentral.com/1471-2350/2/10
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